Teva Pharmaceutical Industries Ltd. reports that the US Food and Drug Administration (FDA) has accepted for review the company’s new drug application (NDA) for the company's hydrocodone bitartrate extended-release (ER) tablets formulated with Teva's proprietary abuse-deterrence technology (CEP-33237). CEP-33237 is an investigational, 12-hour, acetaminophen-free, formulation of extended-release hydrocodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Source: Teva